Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Shenzhen Kangtai Biological Products Co., Ltd.
  6. News
  7. Summary
    300601   CNE100002Q33

SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.

(300601)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Phase III Clinical Fieldwork of the Inactivated COVID-19 Vaccine (Vero Cells) Independently Developed and Manufactured by Shenzhen Kangtai Biological Products Co., Ltd. is Officially Initiated in Malaysia

06/22/2021 | 10:32am EDT

On June 21, local time, phase III clinical fieldwork of the Inactivated COVID-19 Vaccine (Vero cells) independently developed and manufactured by Shenzhen Kangtai Biological Products Co., Ltd. was officially initiated in Malaysia, and the first batch of enrolled subjects was vaccinated on-site. In February this year, BIOKANGTAI and Malaysia's Yong Tai Berhad signed an Agreement on Phase III Clinical Trial of Inactivated COVID-19 Vaccine and Product Procurement, reaching a consensus to further carry out the phase III clinical trials and commercialization of the agreed products in Malaysia. On May 31, the National Pharmaceutical Regulatory Agency (NPRA), Malaysia, approves the clinical trial of the vaccine. Subsequently, on June 11, clinical samples of the vaccine were delivered from Shenzhen, China to Malaysia. In May 2021, the BIOKANGTAI Inactivated COVID-19 Vaccine was granted the Emergency Use Authorization (EUA) in China, making it the sixth COVID-19 vaccine variety approved in China and also the first COVID-19 vaccine variety approved in Guangdong province. Since the commencement of the large-scale vaccination of the vaccine on June 1, the cumulative dose of vaccination has reached millions, according to the statistics of local regulatory authorities, its adverse reaction rate is much lower than the average level, showing its excellent safety. In addition, according to the data of phase I/II clinical trials published on the medRxiv platform and in the National Medical Journal of China, in the phase II clinical trial of the vaccine, the geometric mean titer of neutralizing antibody against the vaccine virus in the vaccine group on day 0-28 of the immunization program is 2.65 times of that of the serum neutralizing antibody of the convalescents, with an expected protection rate of more than 90%.


© S&P Capital IQ 2021
All news about SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
09/24Shenzhen Kangtai Biological Products Co., Ltd. Announces 2021 Interim Distribution Plan..
CI
09/16Shenzhen Kangtai Biological Products Co., Ltd. Approves Interim Cash Dividend for the F..
CI
09/08Shenzhen Kangtai Biological Products Co., Ltd. Announces Recombinant COVID-19 Vaccine (..
CI
08/30Shenzhen Kangtai Biological Products Co., Ltd. Proposes Cash Dividend for the First Hal..
CI
08/29Shenzhen Kangtai Biological Products Co., Ltd. Reports Earnings Results for the Half Ye..
CI
08/02Shenzhen Kangtai Biological Products Co., Ltd. Announces Philippine Food and Drug Admin..
CI
07/13SHENZHEN KANGTAI BIOLOGICAL PRODUCTS : Kangtai Biological to Issue $309 Million Renminbi-D..
MT
06/22Phase III Clinical Fieldwork of the Inactivated COVID-19 Vaccine (Vero Cells) Independe..
CI
05/31SHENZHEN KANGTAI BIOLOGICAL PRODUCTS : Kangtai Biological to List 1.3 Million Newly Unlock..
MT
05/25China's Kangtai Biological, partners agree to run Phase III trial in Chile - Xinhua
RE
More news
Financials
Sales 2021 3 490 M 546 M 546 M
Net income 2021 1 132 M 177 M 177 M
Net cash 2021 3 448 M 540 M 540 M
P/E ratio 2021 65,1x
Yield 2021 0,24%
Capitalization 74 370 M 11 652 M 11 644 M
EV / Sales 2021 20,3x
EV / Sales 2022 12,7x
Nbr of Employees 2 043
Free-Float 96,9%
Chart SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
Duration : Period :
Shenzhen Kangtai Biological Products Co., Ltd. Technical Analysis Chart | 300601 | CNE100002Q33 | MarketScreener
Technical analysis trends SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 108,26 CNY
Average target price 204,43 CNY
Spread / Average Target 88,8%
EPS Revisions
Managers and Directors
Wei Min Du Chairman & General Manager
Xiang Miao Chief Financial Officer & Board Secretary
Zhi Yun Lu Chairman-Supervisory Board
Xiang Ming Li Independent Director
Dong Guang Ma Independent Director
Sector and Competitors